Compare Chiome Bioscience vs Symyx Technologies
Customers evaluate the quality of Chiome Bioscience's products using the following success metrics.
Overview
Chiome Bioscience is 19 yrs old and is based in Japan.
Chiome Bioscience (TYO:4583) leverages the ADLib System, a proprietary monoclonal antibody-generating technology for drug development. The company also provides drug discovery support. It creates lead antibody drugs, engages in the production of specific antibodies against antigens, and conducts research and development through the ADLib System. Chrome Bioscience was founded in 2005 and is based in Tokyo, Japan.
Symyx Technologies is 30 yrs old and is based in United States.
Symyx develops and applies high-speed combinatorial technologies to the discovery of materials for life science, chemical and electronics applications. Symyx provides research services to its partners through its Industry Collaborations business, seeks to license discovered materials through its Proprietary Materials programs, offers access to select instruments and software through its Discovery Tools business, and licenses certain of its patented apparatus and research methodologies through its Intellectual Property Licensing business.
Demo Video
Leadership
Jeryl L Hilleman (Chief Financial Officer)
Investors
Fast Track Initiative and SMBC Venture Capital
Presidio Partners, Venrock
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Chiome Bioscience has not claimed their profile.
Work for Chiome Bioscience? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Chiome Bioscience?
Claim your profile now.
Information not available because Symyx Technologies has not claimed their profile.
Work for Symyx Technologies? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Symyx Technologies?
Claim your profile now.